APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antiviral Drugs for Influenza

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Antiviral Drugs for Influenza Industry Growth and Trends Forecast to 2032

29 December 2025109 pages

Choose your research edition.

Industry ResearchAntiviral Drugs for Influenza Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Antiviral Drugs for Influenza Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Antiviral Drugs for Influenza Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antiviral Drugs for Influenza Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Antiviral Drugs for Influenza Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Antiviral Drugs for Influenza market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Antiviral Drugs for Influenza is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Antiviral Drugs for Influenza is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antiviral Drugs for Influenza is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antiviral Drugs for Influenza include AdvaCare Pharma, Avexima, BioCryst Pharmaceuticals, Daiichi Sankyo, Morningside Pharmaceuticals, Shionogi, Wockhardt, GlaxoSmithKline and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Antiviral Drugs for Influenza market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Antiviral Drugs for Influenza market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Antiviral Drugs for Influenza market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Antiviral Drugs for Influenza.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Antiviral Drugs for Influenza market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Antiviral Drugs for Influenza Market by Company

AdvaCare Pharma

Avexima

BioCryst Pharmaceuticals

Daiichi Sankyo

Morningside Pharmaceuticals

Shionogi

Wockhardt

GlaxoSmithKline

Roche

Teva Pharmaceuticals

Antiviral Drugs for Influenza Segment by Type

Neuraminidase Inhibitors

Polymerase Inhibitors

Antiviral Drugs for Influenza Segment by Application

Over-the-counter (OTC)

Prescription (Rx)

Antiviral Drugs for Influenza Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiviral Drugs for Influenza market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antiviral Drugs for Influenza and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiviral Drugs for Influenza.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antiviral Drugs for Influenza manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Antiviral Drugs for Influenza in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Neuraminidase Inhibitors Table 2. Major Company of Polymerase Inhibitors Table 3. Global Antiviral Drugs for Influenza Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Antiviral Drugs for Influenza Sales by Type (2021-2026) & (K Units) Table 5. Global Antiviral Drugs for Influenza Sales Market Share in Volume by Type (2021-2026) Table 6. Global Antiviral Drugs for Influenza Sales by Type (2021-2026) & (US$ Million) Table 7. Global Antiviral Drugs for Influenza Sales Market Share in Value by Type (2021-2026) Table 8. Global Antiviral Drugs for Influenza Price by Type (2021-2026) & (US$/Unit) Table 9. Global Antiviral Drugs for Influenza Sales by Type (2027-2032) & (K Units) Table 10. Global Antiviral Drugs for Influenza Sales Market Share in Volume by Type (2027-2032) Table 11. Global Antiviral Drugs for Influenza Sales by Type (2027-2032) & (US$ Million) Table 12. Global Antiviral Drugs for Influenza Sales Market Share in Value by Type (2027-2032) Table 13. Global Antiviral Drugs for Influenza Price by Type (2027-2032) & (US$/Unit) Table 14. North America Antiviral Drugs for Influenza Sales by Type (2021-2026) & (K Units) Table 15. North America Antiviral Drugs for Influenza Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Antiviral Drugs for Influenza Sales by Type (2021-2026) & (K Units) Table 17. Europe Antiviral Drugs for Influenza Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Antiviral Drugs for Influenza Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Antiviral Drugs for Influenza Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Antiviral Drugs for Influenza Sales by Type (2021-2026) & (K Units) Table 21. Latin America Antiviral Drugs for Influenza Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Antiviral Drugs for Influenza Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Antiviral Drugs for Influenza Sales by Type (2021-2026) & (US$ Million) Table 24. Antiviral Drugs for Influenza Industry Trends Table 25. Antiviral Drugs for Influenza Industry Drivers Table 26. Antiviral Drugs for Influenza Industry Opportunities and Challenges Table 27. Antiviral Drugs for Influenza Industry Restraints Table 28. Global Antiviral Drugs for Influenza Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Antiviral Drugs for Influenza Revenue Market Share by Company (2021-2026) Table 30. Global Antiviral Drugs for Influenza Sales by Company (2021-2026) & (K Units) Table 31. Global Antiviral Drugs for Influenza Sales Share by Company (2021-2026) Table 32. Global Antiviral Drugs for Influenza Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Antiviral Drugs for Influenza Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Antiviral Drugs for Influenza Major Company Production Sites and Headquarters Table 35. Global Antiviral Drugs for Influenza Company, Product Type & Application Table 36. Global Antiviral Drugs for Influenza Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Antiviral Drugs for Influenza by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Antiviral Drugs for Influenza Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Antiviral Drugs for Influenza Sales by Region (2021-2026) & (K Units) Table 41. Global Antiviral Drugs for Influenza Sales Market Share in Volume by Region (2021-2026) Table 42. Global Antiviral Drugs for Influenza Sales by Region (2021-2026) & (US$ Million) Table 43. Global Antiviral Drugs for Influenza Sales Market Share in Value by Region (2021-2026) Table 44. Global Antiviral Drugs for Influenza Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Antiviral Drugs for Influenza Sales by Region (2027-2032) & (K Units) Table 46. Global Antiviral Drugs for Influenza Sales Market Share in Volume by Region (2027-2032) Table 47. Global Antiviral Drugs for Influenza Sales by Region (2027-2032) & (US$ Million) Table 48. Global Antiviral Drugs for Influenza Sales Market Share in Value by Region (2027-2032) Table 49. Global Antiviral Drugs for Influenza Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Antiviral Drugs for Influenza Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Antiviral Drugs for Influenza Sales by Application (2021-2026) & (K Units) Table 52. Global Antiviral Drugs for Influenza Sales Market Share in Volume by Application (2021-2026) Table 53. Global Antiviral Drugs for Influenza Sales by Application (2021-2026) & (US$ Million) Table 54. Global Antiviral Drugs for Influenza Sales Market Share in Value by Application (2021-2026) Table 55. Global Antiviral Drugs for Influenza Price by Application (2021-2026) & (US$/Unit) Table 56. Global Antiviral Drugs for Influenza Sales by Application (2027-2032) & (K Units) Table 57. Global Antiviral Drugs for Influenza Sales Market Share in Volume by Application (2027-2032) Table 58. Global Antiviral Drugs for Influenza Sales by Application (2027-2032) & (US$ Million) Table 59. Global Antiviral Drugs for Influenza Sales Market Share in Value by Application (2027-2032) Table 60. Global Antiviral Drugs for Influenza Price by Application (2027-2032) & (US$/Unit) Table 61. North America Antiviral Drugs for Influenza Sales by Application (2021-2026) & (K Units) Table 62. North America Antiviral Drugs for Influenza Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Antiviral Drugs for Influenza Sales by Application (2021-2026) & (K Units) Table 64. Europe Antiviral Drugs for Influenza Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Antiviral Drugs for Influenza Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Antiviral Drugs for Influenza Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Antiviral Drugs for Influenza Sales by Application (2021-2026) & (K Units) Table 68. Latin America Antiviral Drugs for Influenza Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Antiviral Drugs for Influenza Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Antiviral Drugs for Influenza Sales by Application (2021-2026) & (US$ Million) Table 71. AdvaCare Pharma Company Information Table 72. AdvaCare Pharma Business Overview Table 73. AdvaCare Pharma Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. AdvaCare Pharma Antiviral Drugs for Influenza Product Portfolio Table 75. AdvaCare Pharma Recent Development Table 76. Avexima Company Information Table 77. Avexima Business Overview Table 78. Avexima Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Avexima Antiviral Drugs for Influenza Product Portfolio Table 80. Avexima Recent Development Table 81. BioCryst Pharmaceuticals Company Information Table 82. BioCryst Pharmaceuticals Business Overview Table 83. BioCryst Pharmaceuticals Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. BioCryst Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio Table 85. BioCryst Pharmaceuticals Recent Development Table 86. Daiichi Sankyo Company Information Table 87. Daiichi Sankyo Business Overview Table 88. Daiichi Sankyo Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Daiichi Sankyo Antiviral Drugs for Influenza Product Portfolio Table 90. Daiichi Sankyo Recent Development Table 91. Morningside Pharmaceuticals Company Information Table 92. Morningside Pharmaceuticals Business Overview Table 93. Morningside Pharmaceuticals Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Morningside Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio Table 95. Morningside Pharmaceuticals Recent Development Table 96. Shionogi Company Information Table 97. Shionogi Business Overview Table 98. Shionogi Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Shionogi Antiviral Drugs for Influenza Product Portfolio Table 100. Shionogi Recent Development Table 101. Wockhardt Company Information Table 102. Wockhardt Business Overview Table 103. Wockhardt Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Wockhardt Antiviral Drugs for Influenza Product Portfolio Table 105. Wockhardt Recent Development Table 106. GlaxoSmithKline Company Information Table 107. GlaxoSmithKline Business Overview Table 108. GlaxoSmithKline Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. GlaxoSmithKline Antiviral Drugs for Influenza Product Portfolio Table 110. GlaxoSmithKline Recent Development Table 111. Roche Company Information Table 112. Roche Business Overview Table 113. Roche Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Roche Antiviral Drugs for Influenza Product Portfolio Table 115. Roche Recent Development Table 116. Teva Pharmaceuticals Company Information Table 117. Teva Pharmaceuticals Business Overview Table 118. Teva Pharmaceuticals Antiviral Drugs for Influenza Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Teva Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio Table 120. Teva Pharmaceuticals Recent Development Table 121. North America Antiviral Drugs for Influenza Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 122. North America Antiviral Drugs for Influenza Sales by Country (2021-2026) & (K Units) Table 123. North America Antiviral Drugs for Influenza Sales Market Share by Country (2021-2026) Table 124. North America Antiviral Drugs for Influenza Sales Forecast by Country (2027-2032) & (K Units) Table 125. North America Antiviral Drugs for Influenza Sales Market Share Forecast by Country (2027-2032) Table 126. North America Antiviral Drugs for Influenza Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. North America Antiviral Drugs for Influenza Market Size by Country (2021-2026) & (US$ Million) Table 128. North America Antiviral Drugs for Influenza Market Share by Country (2021-2026) Table 129. North America Antiviral Drugs for Influenza Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. North America Antiviral Drugs for Influenza Market Share Forecast by Country (2027-2032) Table 131. Europe Antiviral Drugs for Influenza Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 132. Europe Antiviral Drugs for Influenza Sales by Country (2021-2026) & (K Units) Table 133. Europe Antiviral Drugs for Influenza Sales Market Share by Country (2021-2026) Table 134. Europe Antiviral Drugs for Influenza Sales Forecast by Country (2027-2032) & (K Units) Table 135. Europe Antiviral Drugs for Influenza Sales Market Share Forecast by Country (2027-2032) Table 136. Europe Antiviral Drugs for Influenza Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Europe Antiviral Drugs for Influenza Market Size by Country (2021-2026) & (US$ Million) Table 138. Europe Antiviral Drugs for Influenza Market Share by Country (2021-2026) Table 139. Europe Antiviral Drugs for Influenza Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Europe Antiviral Drugs for Influenza Market Share Forecast by Country (2027-2032) Table 141. Asia-Pacific Antiviral Drugs for Influenza Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 142. Asia-Pacific Antiviral Drugs for Influenza Sales by Country (2021-2026) & (K Units) Table 143. Asia-Pacific Antiviral Drugs for Influenza Sales Market Share by Country (2021-2026) Table 144. Asia-Pacific Antiviral Drugs for Influenza Sales Forecast by Country (2027-2032) & (K Units) Table 145. Asia-Pacific Antiviral Drugs for Influenza Sales Market Share Forecast by Country (2027-2032) Table 146. Asia-Pacific Antiviral Drugs for Influenza Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Asia-Pacific Antiviral Drugs for Influenza Market Size by Country (2021-2026) & (US$ Million) Table 148. Asia-Pacific Antiviral Drugs for Influenza Market Share by Country (2021-2026) Table 149. Asia-Pacific Antiviral Drugs for Influenza Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Asia-Pacific Antiviral Drugs for Influenza Market Share Forecast by Country (2027-2032) Table 151. Latin America Antiviral Drugs for Influenza Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 152. Latin America Antiviral Drugs for Influenza Sales by Country (2021-2026) & (K Units) Table 153. Latin America Antiviral Drugs for Influenza Sales Market Share by Country (2021-2026) Table 154. Latin America Antiviral Drugs for Influenza Sales Forecast by Country (2027-2032) & (K Units) Table 155. Latin America Antiviral Drugs for Influenza Sales Market Share Forecast by Country (2027-2032) Table 156. Latin America Antiviral Drugs for Influenza Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Latin America Antiviral Drugs for Influenza Market Size by Country (2021-2026) & (US$ Million) Table 158. Latin America Antiviral Drugs for Influenza Market Share by Country (2021-2026) Table 159. Latin America Antiviral Drugs for Influenza Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Latin America Antiviral Drugs for Influenza Market Share Forecast by Country (2027-2032) Table 161. Middle East and Africa Antiviral Drugs for Influenza Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 162. Middle East and Africa Antiviral Drugs for Influenza Sales by Country (2021-2026) & (K Units) Table 163. Middle East and Africa Antiviral Drugs for Influenza Sales Market Share by Country (2021-2026) Table 164. Middle East and Africa Antiviral Drugs for Influenza Sales Forecast by Country (2027-2032) & (K Units) Table 165. Middle East and Africa Antiviral Drugs for Influenza Sales Market Share Forecast by Country (2027-2032) Table 166. Middle East and Africa Antiviral Drugs for Influenza Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Middle East and Africa Antiviral Drugs for Influenza Market Size by Country (2021-2026) & (US$ Million) Table 168. Middle East and Africa Antiviral Drugs for Influenza Market Share by Country (2021-2026) Table 169. Middle East and Africa Antiviral Drugs for Influenza Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Middle East and Africa Antiviral Drugs for Influenza Market Share Forecast by Country (2027-2032) Table 171. Key Raw Materials Table 172. Raw Materials Key Suppliers Table 173. Antiviral Drugs for Influenza Distributors List Table 174. Antiviral Drugs for Influenza Customers List Table 175. Research Programs/Design for This Report Table 176. Authors List of This Report Table 177. Secondary Sources Table 178. Primary Sources List of Figures Figure 1. Antiviral Drugs for Influenza Image Figure 2. Global Antiviral Drugs for Influenza Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antiviral Drugs for Influenza Market Size (2021-2032) & (US$ Million) Figure 4. Global Antiviral Drugs for Influenza Sales (2021-2032) & (K Units) Figure 5. Neuraminidase Inhibitors Image Figure 6. Global Neuraminidase Inhibitors Sales YoY Growth (2021-2032) & (K Units) Figure 7. Polymerase Inhibitors Image Figure 8. Global Polymerase Inhibitors Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Antiviral Drugs for Influenza Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Antiviral Drugs for Influenza Market Share by Type 2025 VS 2032 Figure 11. North America Antiviral Drugs for Influenza Sales Market Share in Volume by Type in 2025 Figure 12. North America Antiviral Drugs for Influenza Sales Market Share in Value by Type in 2025 Figure 13. Europe Antiviral Drugs for Influenza Sales Market Share in Volume by Type in 2025 Figure 14. Europe Antiviral Drugs for Influenza Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Antiviral Drugs for Influenza Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Antiviral Drugs for Influenza Sales Market Share in Value by Type in 2025 Figure 17. Latin America Antiviral Drugs for Influenza Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Antiviral Drugs for Influenza Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Antiviral Drugs for Influenza Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Antiviral Drugs for Influenza Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Antiviral Drugs for Influenza Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Over-the-counter (OTC) Image Figure 24. Global Over-the-counter (OTC) Sales YoY Growth (2021-2032) & (K Units) Figure 25. Prescription (Rx) Image Figure 26. Global Prescription (Rx) Sales YoY Growth (2021-2032) & (K Units) Figure 27. Global Antiviral Drugs for Influenza Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Antiviral Drugs for Influenza Market Share by Application 2025 VS 2032 Figure 29. North America Antiviral Drugs for Influenza Sales Market Share in Volume by Application in 2025 Figure 30. North America Antiviral Drugs for Influenza Sales Market Share in Value by Application in 2025 Figure 31. Europe Antiviral Drugs for Influenza Sales Market Share in Volume by Application in 2025 Figure 32. Europe Antiviral Drugs for Influenza Sales Market Share in Value by Application in 2025 Figure 33. Asia-Pacific Antiviral Drugs for Influenza Sales Market Share in Volume by Application in 2025 Figure 34. Asia-Pacific Antiviral Drugs for Influenza Sales Market Share in Value by Application in 2025 Figure 35. Latin America Antiviral Drugs for Influenza Sales Market Share in Volume by Application in 2025 Figure 36. Latin America Antiviral Drugs for Influenza Sales Market Share in Value by Application in 2025 Figure 37. Middle East and Africa Antiviral Drugs for Influenza Sales Market Share in Volume by Application in 2025 Figure 38. Middle East and Africa Antiviral Drugs for Influenza Sales Market Share in Value by Application in 2025 Figure 39. North America Antiviral Drugs for Influenza Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 40. North America Antiviral Drugs for Influenza Sales Share by Country: 2021 VS 2025 VS 2032 Figure 41. North America Antiviral Drugs for Influenza Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. North America Antiviral Drugs for Influenza Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Antiviral Drugs for Influenza Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. Europe Antiviral Drugs for Influenza Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Antiviral Drugs for Influenza Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Antiviral Drugs for Influenza Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Asia-Pacific Antiviral Drugs for Influenza Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Asia-Pacific Antiviral Drugs for Influenza Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Antiviral Drugs for Influenza Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Asia-Pacific Antiviral Drugs for Influenza Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Antiviral Drugs for Influenza Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Latin America Antiviral Drugs for Influenza Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Antiviral Drugs for Influenza Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Antiviral Drugs for Influenza Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Middle East and Africa Antiviral Drugs for Influenza Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Middle East and Africa Antiviral Drugs for Influenza Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Antiviral Drugs for Influenza Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Middle East and Africa Antiviral Drugs for Influenza Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Antiviral Drugs for Influenza Value Chain Figure 60. Key Raw Materials Price Figure 61. Manufacturing Cost Structure Figure 62. Antiviral Drugs for Influenza Production Mode & Process Figure 63. Direct Comparison with Distribution Share Figure 64. Distributors Profiles Figure 65. Years Considered Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Neuraminidase Inhibitors
  • Polymerase Inhibitors
Applications
  • Over-the-counter (OTC)
  • Prescription (Rx)
Companies covered
  • AdvaCare Pharma
  • Avexima
  • BioCryst Pharmaceuticals
  • Daiichi Sankyo
  • Morningside Pharmaceuticals
  • Shionogi
  • Wockhardt
  • GlaxoSmithKline
  • Roche
  • Teva Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antiviral Drugs for Influenza Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Antiviral Drugs for Influenza Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Antiviral Drugs for Influenza Market by Type
  6. 1.3.1 Neuraminidase Inhibitors
  7. 1.3.2 Polymerase Inhibitors
  8. 1.4 Global Antiviral Drugs for Influenza Market Size by Type
  9. 1.4.1 Global Antiviral Drugs for Influenza Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Antiviral Drugs for Influenza Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Antiviral Drugs for Influenza Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Antiviral Drugs for Influenza Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Antiviral Drugs for Influenza Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Antiviral Drugs for Influenza Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Antiviral Drugs for Influenza Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Antiviral Drugs for Influenza Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Antiviral Drugs for Influenza Industry Trends
  2. 2.2 Antiviral Drugs for Influenza Industry Drivers
  3. 2.3 Antiviral Drugs for Influenza Industry Opportunities and Challenges
  4. 2.4 Antiviral Drugs for Influenza Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Antiviral Drugs for Influenza Revenue (2021-2026)
  2. 3.2 Global Top Players by Antiviral Drugs for Influenza Sales (2021-2026)
  3. 3.3 Global Top Players by Antiviral Drugs for Influenza Price (2021-2026)
  4. 3.4 Global Antiviral Drugs for Influenza Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antiviral Drugs for Influenza Major Company Production Sites & Headquarters
  6. 3.6 Global Antiviral Drugs for Influenza Company, Product Type & Application
  7. 3.7 Global Antiviral Drugs for Influenza Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antiviral Drugs for Influenza Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antiviral Drugs for Influenza Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antiviral Drugs for Influenza Tier 1, Tier 2, and Tier 3
4 Antiviral Drugs for Influenza Regional Status and Outlook
  1. 4.1 Global Antiviral Drugs for Influenza Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Antiviral Drugs for Influenza Historic Market Size by Region
  3. 4.2.1 Global Antiviral Drugs for Influenza Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Antiviral Drugs for Influenza Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Antiviral Drugs for Influenza Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Antiviral Drugs for Influenza Forecasted Market Size by Region
  7. 4.3.1 Global Antiviral Drugs for Influenza Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Antiviral Drugs for Influenza Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Antiviral Drugs for Influenza Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Antiviral Drugs for Influenza by Application
  1. 5.1 Antiviral Drugs for Influenza Market by Application
  2. 5.1.1 Over-the-counter (OTC)
  3. 5.1.2 Prescription (Rx)
  4. 5.2 Global Antiviral Drugs for Influenza Market Size by Application
  5. 5.2.1 Global Antiviral Drugs for Influenza Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Antiviral Drugs for Influenza Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Antiviral Drugs for Influenza Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Antiviral Drugs for Influenza Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Antiviral Drugs for Influenza Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Antiviral Drugs for Influenza Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Antiviral Drugs for Influenza Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Antiviral Drugs for Influenza Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 AdvaCare Pharma
  2. 6.1.1 AdvaCare Pharma Company Information
  3. 6.1.2 AdvaCare Pharma Business Overview
  4. 6.1.3 AdvaCare Pharma Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 AdvaCare Pharma Antiviral Drugs for Influenza Product Portfolio
  6. 6.1.5 AdvaCare Pharma Recent Developments
  7. 6.2 Avexima
  8. 6.2.1 Avexima Company Information
  9. 6.2.2 Avexima Business Overview
  10. 6.2.3 Avexima Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Avexima Antiviral Drugs for Influenza Product Portfolio
  12. 6.2.5 Avexima Recent Developments
  13. 6.3 BioCryst Pharmaceuticals
  14. 6.3.1 BioCryst Pharmaceuticals Company Information
  15. 6.3.2 BioCryst Pharmaceuticals Business Overview
  16. 6.3.3 BioCryst Pharmaceuticals Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 BioCryst Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
  18. 6.3.5 BioCryst Pharmaceuticals Recent Developments
  19. 6.4 Daiichi Sankyo
  20. 6.4.1 Daiichi Sankyo Company Information
  21. 6.4.2 Daiichi Sankyo Business Overview
  22. 6.4.3 Daiichi Sankyo Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Daiichi Sankyo Antiviral Drugs for Influenza Product Portfolio
  24. 6.4.5 Daiichi Sankyo Recent Developments
  25. 6.5 Morningside Pharmaceuticals
  26. 6.5.1 Morningside Pharmaceuticals Company Information
  27. 6.5.2 Morningside Pharmaceuticals Business Overview
  28. 6.5.3 Morningside Pharmaceuticals Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Morningside Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
  30. 6.5.5 Morningside Pharmaceuticals Recent Developments
  31. 6.6 Shionogi
  32. 6.6.1 Shionogi Company Information
  33. 6.6.2 Shionogi Business Overview
  34. 6.6.3 Shionogi Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Shionogi Antiviral Drugs for Influenza Product Portfolio
  36. 6.6.5 Shionogi Recent Developments
  37. 6.7 Wockhardt
  38. 6.7.1 Wockhardt Company Information
  39. 6.7.2 Wockhardt Business Overview
  40. 6.7.3 Wockhardt Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Wockhardt Antiviral Drugs for Influenza Product Portfolio
  42. 6.7.5 Wockhardt Recent Developments
  43. 6.8 GlaxoSmithKline
  44. 6.8.1 GlaxoSmithKline Company Information
  45. 6.8.2 GlaxoSmithKline Business Overview
  46. 6.8.3 GlaxoSmithKline Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 GlaxoSmithKline Antiviral Drugs for Influenza Product Portfolio
  48. 6.8.5 GlaxoSmithKline Recent Developments
  49. 6.9 Roche
  50. 6.9.1 Roche Company Information
  51. 6.9.2 Roche Business Overview
  52. 6.9.3 Roche Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Roche Antiviral Drugs for Influenza Product Portfolio
  54. 6.9.5 Roche Recent Developments
  55. 6.10 Teva Pharmaceuticals
  56. 6.10.1 Teva Pharmaceuticals Company Information
  57. 6.10.2 Teva Pharmaceuticals Business Overview
  58. 6.10.3 Teva Pharmaceuticals Antiviral Drugs for Influenza Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Teva Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
  60. 6.10.5 Teva Pharmaceuticals Recent Developments
7 North America by Country
  1. 7.1 North America Antiviral Drugs for Influenza Sales by Country
  2. 7.1.1 North America Antiviral Drugs for Influenza Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Antiviral Drugs for Influenza Sales by Country (2021-2026)
  4. 7.1.3 North America Antiviral Drugs for Influenza Sales Forecast by Country (2027-2032)
  5. 7.2 North America Antiviral Drugs for Influenza Market Size by Country
  6. 7.2.1 North America Antiviral Drugs for Influenza Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Antiviral Drugs for Influenza Market Size by Country (2021-2026)
  8. 7.2.3 North America Antiviral Drugs for Influenza Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Antiviral Drugs for Influenza Sales by Country
  2. 8.1.1 Europe Antiviral Drugs for Influenza Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Antiviral Drugs for Influenza Sales by Country (2021-2026)
  4. 8.1.3 Europe Antiviral Drugs for Influenza Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Antiviral Drugs for Influenza Market Size by Country
  6. 8.2.1 Europe Antiviral Drugs for Influenza Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Antiviral Drugs for Influenza Market Size by Country (2021-2026)
  8. 8.2.3 Europe Antiviral Drugs for Influenza Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Antiviral Drugs for Influenza Sales by Country
  2. 9.1.1 Asia-Pacific Antiviral Drugs for Influenza Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Antiviral Drugs for Influenza Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Antiviral Drugs for Influenza Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Antiviral Drugs for Influenza Market Size by Country
  6. 9.2.1 Asia-Pacific Antiviral Drugs for Influenza Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Antiviral Drugs for Influenza Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Antiviral Drugs for Influenza Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Antiviral Drugs for Influenza Sales by Country
  2. 10.1.1 South America Antiviral Drugs for Influenza Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Antiviral Drugs for Influenza Sales by Country (2021-2026)
  4. 10.1.3 South America Antiviral Drugs for Influenza Sales Forecast by Country (2027-2032)
  5. 10.2 South America Antiviral Drugs for Influenza Market Size by Country
  6. 10.2.1 South America Antiviral Drugs for Influenza Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Antiviral Drugs for Influenza Market Size by Country (2021-2026)
  8. 10.2.3 South America Antiviral Drugs for Influenza Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Antiviral Drugs for Influenza Sales by Country
  2. 11.1.1 Middle East and Africa Antiviral Drugs for Influenza Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Antiviral Drugs for Influenza Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Antiviral Drugs for Influenza Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Antiviral Drugs for Influenza Market Size by Country
  6. 11.2.1 Middle East and Africa Antiviral Drugs for Influenza Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Antiviral Drugs for Influenza Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Antiviral Drugs for Influenza Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Antiviral Drugs for Influenza Value Chain Analysis
  2. 12.1.1 Antiviral Drugs for Influenza Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Antiviral Drugs for Influenza Production Mode & Process
  7. 12.2 Antiviral Drugs for Influenza Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Antiviral Drugs for Influenza Distributors
  10. 12.2.3 Antiviral Drugs for Influenza Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst